Wuhan Jissbon Sanitary Product Co. Ltd.

Primary objective: To study the pharmacokinetic characteristics of the test preparation drospirenone ethinyl estradiol tablets (specification: each tablet contains 0.03 mg ethinyl estradiol and 3 mg drospirenone, produced by Love Health Industry Co., Ltd.) and the reference preparation drospirenone ethinyl estradiol tablets (Yasmin®, specification: each tablet contains 0.03 mg ethinyl estradiol and 3 mg drospirenone; licensed by Bayer Australia Ltd, produced by Bayer Weimar GmbH & Co. KG.) in healthy adult subjects after single oral administration in fasting and fed state, and to evaluate the bioequivalence of the two preparations after oral administration in fasting and fed state. Secondary objective: To study the safety of the test preparation drospirenone ethinyl estradiol tablets (specification: each tablet contains 0.03 mg ethinyl estradiol and 3 mg drospirenone) and the reference preparation drospirenone ethinyl estradiol tablets (Yasmin®) (specification: each tablet contains 0.03 mg ethinyl estradiol and 3 mg drospirenone) in healthy subjects.

The main purpose of the study is to study the pharmacokinetics of levonorgestrel tablets (specification: 1.5 mg; test preparation) developed by Love Health Industry Co., Ltd. in healthy female subjects under fasting and postprandial conditions, using levonorgestrel tablets (specification: 1.5 mg, trade name: Baoshiting®) held by Gedeon Richter Plc. as the reference preparation, and to evaluate whether the test preparation and the reference preparation are bioequivalent. The secondary purpose of the study is to observe the safety of oral administration of the test preparation and the reference preparation in healthy female subjects.